Executive Summary
•UNH trades at 17.2x NTM P/E, an 8% discount to its 2 year average of 18.7x, as the market prices in regulatory overhang and Medicare Advantage cost pressure.
•Forward EPS of $22.01 implies a 62% recovery from depressed TTM EPS of $13.60, driven by pricing actions and Optum Health margin normalisation.
•Consensus price target of $470.11 offers 24% upside, but the DOJ antitrust probe and V28 coding headwinds remain the key swing factors.
•Optum Health margin recovery is the critical earnings driver, with Optum Rx facing PBM reform risk and Optum Insight providing stable high margin growth.
Financial Snapshot
•Revenue TTM: $450.53b (YoY growth not disclosed)
•EPS TTM: $13.60 (net margin 3.1%)
•Gross margin TTM: 19.7%
•Operating margin TTM: 7.1%
•Net margin TTM: 3.1%
•ROE TTM: 14.2%
•Debt/Equity: 69.2%
•Forward EPS NTM: $22.01 (consensus as of 2026-10-13)
•Forward revenue NTM: $445.99b (+3.0% consensus growth)
•Forward EPS growth: 14.2%
•FY+2 EPS estimate: $22.62
•FY+2 revenue estimate: $459.21b
Forward Outlook
•Revenue NTM consensus: $445.99b (+3.0% YoY)
•EPS NTM consensus: $22.01, implying 17.2x forward P/E at the current price
•FY+2 EPS consensus: $22.62, implying 16.8x forward P/E
•Net margin trajectory: expected to recover from 3.1% TTM to ~5.1% NTM
•Optum Health margin recovery expected to drive consolidated operating margin improvement
•Medicare Advantage membership attrition expected to moderate in 2027
•Risk adjustment V28 coding headwinds to annualise by mid 2026
•2026 guidance credibility remains a key focus after the 2025 EPS reset
Valuation Analysis
•NTM P/E: 17.2x (vs 2 year average 18.7x, -8%)
•NTM P/S: 0.76x (forward)
•NTM EV/EBIT: 13.2x (vs 2 year average 12.8x, +3%)
•NTM EV/EBITDA: 11.6x (vs 2 year average 11.5x, +1%)
•NTM EV/Rev: 0.9x (vs 2 year average 1.0x, -11%)
•LF P/BV: 3.5x (vs 2 year average 4.1x, -15%)
•Implied price at average BF P/E: $412.29
•Implied price at average BF EV/EBITDA: $376.32
•Implied price at average BF EV/EBIT: $366.80
•Implied price at average BF EV/Rev: $434.87
•Implied price at average LF P/BV: $443.63
•Consensus price target: $470.11 (median $490, range $373 to $529)
•Current price: $378.99 (52 week range $255.97 to $461.62)
•ELV: ~18.8x TTM P/E, $92.0b market cap, managed care peer
•CI: ~11.7x TTM P/E, $74.7b market cap, PBM and insurance mix
•HUM: ~39.8x TTM P/E, $50.5b market cap, Medicare Advantage pure play
•CVS: ~23.0x TTM P/E, $111.6b market cap, PBM and retail pharmacy
Key Risks & Catalysts
Risks
•Medical loss ratio pressure from elevated inpatient and outpatient utilisation trends
•Medicare Advantage rate notice for 2026 and 2027 may not fully cover cost trends
•V28 risk adjustment coding headwinds reducing revenue and margins
•DOJ antitrust probe into PBM and Medicare billing practices, with potential fines or structural remedies
•PBM transparency reform legislation could pressure Optum Rx margins
•Optum Health margin recovery slower than expected due to utilisation and coding
•Membership attrition in Medicare Advantage due to benefit cuts and competition
•2026 guidance credibility risk after the 2025 EPS reset, with potential for further downward revisions
•High debt/equity of 69.2% in a rising rate environment
•Regulatory overhang from the cyberattack and ongoing investigations
Catalysts
•Successful 2026 guidance reaffirmation and EPS recovery
•Optum Health margin recovery as utilisation normalises and coding adjustments annualise
•Favourable Medicare Advantage rate notice for 2027
•Resolution of the DOJ probe with a manageable fine
•PBM reform that is less punitive than feared
•Continued buybacks and dividend growth
•AI and data analytics investments driving Optum Insight growth
•Membership stabilisation and potential reacceleration in 2027
Investment Thesis
UnitedHealth Group is a high quality franchise trading at a rare discount to its historical valuation. The forward P/E of 17.2x is 8% below its 2 year average, and P/BV of 3.5x is 15% below average, reflecting a confluence of regulatory and cost headwinds that have depressed earnings. The TTM net margin of 3.1% is unsustainably low, dragged by the Q1 2025 charge and elevated medical costs. Forward consensus EPS of $22.01 implies a net margin recovery to ~5.1%, achievable through pricing actions, cost controls, and the annualisation of V28 coding headwinds.
The key swing factor is Optum Health margin recovery. Optum Health has been the drag on consolidated margins due to utilisation pressure and risk adjustment coding, but management has levers to restore profitability. Optum Rx faces PBM reform risk, though much of the regulatory overhang appears priced in at current multiples. Optum Insight provides stable, high margin growth. The DOJ antitrust probe is a genuine risk, but a manageable fine is the base case.
At $378.99, UNH offers 24% upside to the consensus price target of $470.11. We recommend Buy with a 12 month price target of $460, based on ~21x NTM EPS of $22.01, a slight premium to the historical average to reflect recovery potential. Key catalysts include the 2026 guidance reaffirmation, Optum Health margin normalisation, and a favourable 2027 Medicare Advantage rate notice. The principal risks are a worse than expected DOJ outcome and continued MLR pressure.
